Live Breaking News & Updates on Michaelg Palfreyman

Stay updated with breaking news from Michaelg palfreyman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Michaelg Palfreyman , Alex Kelman , Gabriel Fahel , Aaron Bartlone , Alex Belser , Tina Mueller , Magdyl Shenouda , Joan Krakowsky , Erik Stang , Sebastian Krempien , Michaele Morgan , Ken Avery , Kimball Johnson , Alex Nivorozhkin , Pradip Pathare , Amyc Reichelt , Richa Tyagi , Clinton Canal , Joshuaa Hartsel , Maria Johnson , Geoff Varty , Samir Inamdar , Pradeepj Nathan , Doug Drysdale ,

Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

TORONTO, November 15, 2023 Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience ("SFN") taking place November 11-15, 2022, in Washington, D.C. ....

United States , United Kingdom , Clintone Canal , Michaele Morgan , Pradip Pathare , Richa Tyagi , Erik Stang , Joshuaa Hartsel , Gabriel Fahel , Geoff Varty , Geoffreyb Varty , Amyc Reichelt , Alex Nivorozhkin , Ken Avery , Tinaa Mueller , Michaelg Palfreyman , Exchange Commission , Society For Neuroscience , Head Of Research Development At Cybin , Cybin Inc , Neither The Neo Exchange Inc , Drug Administration , Health Canada , Mood Disorder , Neo Exchange , Media Contact ,

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

TORONTO - Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today. ....

United States , United Kingdom , Doug Drysdale , Lynn Marie Morski , Joshuaa Hartsel , Erik Stang , Alex Nivorozhkin , Geoffreyb Varty , Ken Avery , Geoff Varty , Clintone Canal , Michael Palfreyman , Tinaa Mueller , Michaelg Palfreyman , Gabriel Fahel , Michaele Morgan , Head Of Research , Cybin Inc , Psychedelic Medicine Association , Exchange Commission , Drug Administration , Neuropsychiatric Drug Development Summit , Health Canada , Chief Executive Officer , Making Psychedelic Clinical Trials , Mitigating Practical Burdens ,

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

- Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” -

- Highlights preclinical work done to support. ....

United States , United Kingdom , Erik Stang , Geoff Varty , Lynn Marie Morski , Clintone Canal , Michaele Morgan , Michael Palfreyman , Geoffreyb Varty , Alex Nivorozhkin , Doug Drysdale , Ken Avery , Joshuaa Hartsel , Tinaa Mueller , Michaelg Palfreyman , Exchange Commission , Health Canada , Neuropsychiatric Drug Development Summit , Head Of Research , Drug Administration , Cybin Inc , Psychedelic Medicine Association , Development For Cybin , Chief Executive Officer , Psychedelic Workshop , Psychedelic Clinical Trials ,

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings

Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “
Transaction”).
Transaction Highlights
Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments.
Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, as well as six patent applications.
Adelia contributes an expanding library of psychedelic derivative drug development candidates. The first lead compounds are expected to enter clinical studies in 2021, subject to receipt of approvals. ....

United States , Northeastern University , Brett Greene , Michaelg Palfreyman , Michael Palfreyman , Doug Drysdale , Alex Nivorozhkin , Eli Lilly , Brettj Greene , Development Officer , Cybin Corp , Nova Capital International , Cybin Inc , Drug Administration , Cybin Us Holdings Inc , Health Canada , Chief Executive Officer , Chief Strategy Officer , Drug Discovery , Chief Operating Officer , Chief Scientific , Chief Research , Chief Innovation , Adelia Shareholders , Classb Share , Classb Shares ,